These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 12213951

  • 1. Estrogen-receptor polymorphism and hormone-replacement therapy.
    Garrido JA.
    N Engl J Med; 2002 Sep 05; 347(10):762-3; author reply 762-3. PubMed ID: 12213951
    [No Abstract] [Full Text] [Related]

  • 2. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease.
    Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER.
    N Engl J Med; 2002 Mar 28; 346(13):967-74. PubMed ID: 11919305
    [Abstract] [Full Text] [Related]

  • 3. Individualized hormone-replacement therapy?
    Krauss RM.
    N Engl J Med; 2002 Mar 28; 346(13):1017-8. PubMed ID: 11919312
    [No Abstract] [Full Text] [Related]

  • 4. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH.
    Arch Intern Med; 2002 Mar 28; 156(15):1693-700. PubMed ID: 8694668
    [Abstract] [Full Text] [Related]

  • 5. Should we measure lipoprotein Lp(a)?
    Wilson PW, Kannel WB.
    Arch Intern Med; 1997 Jun 09; 157(11):1161-2. PubMed ID: 9183225
    [No Abstract] [Full Text] [Related]

  • 6. Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?
    Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, Brandi ML.
    Menopause; 2006 Jun 09; 13(3):451-61. PubMed ID: 16735942
    [Abstract] [Full Text] [Related]

  • 7. Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: a randomized controlled trial.
    Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P.
    Menopause; 1998 Jun 09; 5(3):157-62. PubMed ID: 9774761
    [Abstract] [Full Text] [Related]

  • 8. Hormone replacement therapy and cardiovascular disease: the human model.
    Sullivan JM.
    Br J Obstet Gynaecol; 1996 May 09; 103 Suppl 13():59-65; discussion 66-7. PubMed ID: 8624345
    [No Abstract] [Full Text] [Related]

  • 9. [Prevention of cardiovascular diseases by hormone replacement in postmenopause].
    Windler E.
    Zentralbl Gynakol; 1996 May 09; 118(4):188-97. PubMed ID: 8651005
    [Abstract] [Full Text] [Related]

  • 10. Lipid profile during hormone replacement therapy: effect of different progestins?
    Campagnoli C, Belforte P, Di Sario MM, Lesca L.
    Zentralbl Gynakol; 1997 May 09; 119 Suppl 2():1-6. PubMed ID: 9361391
    [Abstract] [Full Text] [Related]

  • 11. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I, Koch K.
    Climacteric; 2002 Dec 09; 5(4):341-50. PubMed ID: 12626213
    [Abstract] [Full Text] [Related]

  • 12. Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial.
    Falkeborn M, Lithell H, Persson I, Vessby B, Naessén T.
    Climacteric; 2002 Sep 09; 5(3):240-8. PubMed ID: 12419082
    [Abstract] [Full Text] [Related]

  • 13. Effect of estrogen replacement therapy on lipids. Implications for cardiovascular risk.
    LaRosa JC.
    J Reprod Med; 1985 Oct 09; 30(10 Suppl):811-3. PubMed ID: 4078813
    [Abstract] [Full Text] [Related]

  • 14. ESR1 and APOE gene polymorphisms, serum lipids, and hormonal replacement therapy.
    Almeida S, Fiegenbaum M, de Andrade FM, Osório-Wender MC, Hutz MH.
    Maturitas; 2006 May 20; 54(2):119-26. PubMed ID: 16242874
    [Abstract] [Full Text] [Related]

  • 15. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess.
    Rosenson RS.
    Arch Intern Med; 1996 Jun 24; 156(12):1278-84. PubMed ID: 8651835
    [Abstract] [Full Text] [Related]

  • 16. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
    Meuwissen JH, Beijers-De Bie L, Vihtamaki T, Tuimala R, Siseles N, Magaril C, The HS, Houben PW, Murga M, Spielmann D, De Villiers TJ.
    Gynecol Endocrinol; 2002 Apr 24; 16(2):155-62. PubMed ID: 12012627
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T, Creatsas G, Rechberger T, Depypere H, Erenus M, Quail D, Arndt T, Bonnar J, Euralox 1 Study Group.
    Climacteric; 2001 Dec 24; 4(4):320-31. PubMed ID: 11770189
    [Abstract] [Full Text] [Related]

  • 18. Niacin after coronary bypass grafting and for coronary disease prevention.
    Parsons WB.
    Circulation; 2001 Jul 10; 104(2):E7. PubMed ID: 11447097
    [No Abstract] [Full Text] [Related]

  • 19. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ, Kane JP.
    Dis Mon; 1998 Jan 10; 44(1):1-40. PubMed ID: 9457050
    [No Abstract] [Full Text] [Related]

  • 20. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins.
    Marsh MS, Crook D, Whitcroft SI, Worthington M, Whitehead MI, Stevenson JC.
    Obstet Gynecol; 1994 Jan 10; 83(1):19-23. PubMed ID: 8272301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.